Steris Shows Improved Relative Strength; Still Shy Of Benchmark

Steris (STE) had its Relative Strength (RS) Rating upgraded from 67 to 71 Friday — a welcome improvement, but still short of the 80 or better score you prefer to see.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock’s price behavior over the trailing 52 weeks compares to all the other stocks in our database.

Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating in the early stages of their moves. See if Steris can continue to rebound and hit that benchmark.

See How IBD Helps You Make More Money In Stocks

Steris is working on a flat base with a 226.10 buy point. See if it can break out in volume at least 40% above average.

Earnings grew 33% last quarter, up from 0% in the prior report. Revenue also increased, from 6% to 45%. Keep an eye out for the company’s next round of numbers on or around Nov. 2.

The company earns the No. 5 rank among its peers in the Medical-Systems/Equipment industry group. Intuitive Surgical (ISRG) and Omnicell (OMCL) are also among the group’s highest-rated stocks.


Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Find Top Stocks Near A Buy Point With IBD Leaderboard

Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button